drugset / Trial / NCT02537171
Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
Phase 3
Unknown
40 enrolled
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is to evaluate the efficacy of Apatinib in patients with advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction.
Timeline
- Start
- 2015-07
- Primary completion
- 2016-08
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rivoceranib | Small molecule | 500 mg | Oral |
| Comparator | Rivoceranib | Small molecule | 750 mg | Oral |